Matching trials
1,853 results
- TOPSIndependent statistical analysis of Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity): primary endpoint results, effect…
- Torlak-300Independent statistical analysis of Phase 3 Trial of Serbian Seasonal Influenza Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02935192).
- TOSCAIndependent statistical analysis of A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy: primary endpoint results, effect estimate…
- TRAIN-2Independent statistical analysis and educational interpretation of TRAIN-2, a randomized phase 3 trial evaluating neoadjuvant chemotherapy strategies with pertuzumab in HER2-positive breast cancer.
- TRANSFORMIndependent statistical analysis of the randomized phase 3 TRANSFORM trial of JCAR017 versus standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas.
- TRANSFORM-HFComplete statistical analysis of TRANSFORM-HF, the randomized phase 3 comparison of torsemide versus furosemide for management of heart failure, including time-to-event, rehospitalization, quality-of-life, and depression analyses.
- TRANSIT-1Independent statistical analysis of the phase 3 TRANSIT-1 study evaluating the tolerability and safety of transitioning patients with pulmonary arterial hypertension from inhaled treprostinil to oral selexipag.
- TREAT-COVIDIndependent statistical analysis of TREAT-COVID (NCT04351516), a randomized phase 2/3 trial evaluating hydroxychloroquine versus placebo in older adults with COVID-19. Includes trial design, endpoints, planned methodology, and statistical interpretation.
- TRFIndependent statistical analysis of Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TRIBEIndependent statistical analysis of TRIBE (NCT00719797), a phase 3 randomized trial comparing bevacizumab with FOLFOXIRI versus bevacizumab with FOLFIRI as first-line therapy for metastatic colorectal cancer.
- TRILOGYIndependent statistical analysis of Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TRINOVA-1Independent statistical analysis of TRINOVA-1, a phase 3 randomized trial evaluating AMG 386 or placebo with weekly paclitaxel chemotherapy in ovarian, primary peritoneal, and fallopian tube cancer.
- TRINOVA-2Independent statistical analysis of the randomized phase 3 TRINOVA-2 trial evaluating AMG 386 (trebananib) plus PLD versus placebo plus PLD in ovarian cancer and related gynecologic cancers.
- TRISSAn independent statistical analysis of TRISS (NCT01485315), a phase 3 randomized trial evaluating transfusion requirements in septic shock, including design, endpoints, planned statistical methods, and interpretation.
- TRITON3Independent statistical analysis of A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency: primary endpoint results, effect estimate with confidence…
- TRIUMPH-2Independent statistical analysis of TRIUMPH-2, a randomized, double-blind phase 3 study of retatrutide in participants with type 2 diabetes mellitus who have obesity or overweight.
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- TULIP SLE LTEIndependent statistical analysis of Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TURQUOISE-CPBIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4…
- Tysabri JapanIndependent statistical analysis of Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- UNCOVER-3Independent statistical analysis of A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01646177).
- UNIFIIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis: primary endpoint results, effect estimate…
- UNIVERSEIndependent statistical analysis of Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure: primary endpoint results, effect estimate…
- VA NEPHRON-DComplete statistical analysis of VA NEPHRON-D, a randomized phase 3 trial evaluating combination ARB and ACEI therapy versus ARB monotherapy in patients with diabetic nephropathy, including time-to-event endpoints, hazard ratios, confidence intervals,…
- VALUEIndependent statistical analysis of the VALUE phase 3 trial comparing valsartan and amlodipine in essential hypertension, including trial design, the registered composite cardiac endpoint, planned statistical analysis, and interpretation.
- VAST-DComplete statistical analysis of VAST-D, the phase 3 randomized trial of switching to bupropion-SR versus augmentation with bupropion-SR or aripiprazole for major depressive disorder, including remission, response, relapse, statistical methodology, safety, and…
- VEGAIndependent statistical analysis of Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02396316).
- VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…
- VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…
- VENICEComplete statistical analysis of the phase 3 VENICE trial of aflibercept plus docetaxel in metastatic androgen independent prostate cancer, including randomized trial design, overall survival, hazard ratio interpretation, and time-to-event methodology.
- VENICE IIIndependent statistical analysis of A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer…
- VENTUREIndependent statistical analysis of the VENTURE phase 3 trial evaluating dupilumab in patients with severe steroid-dependent asthma, including its randomized design, oral corticosteroid reduction endpoints, ANCOVA, logistic regression, missing-data methods, and reported…
- VERITASIndependent statistical analysis of A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal…
- VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…
- VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…
- VICTORION-2PAn independent statistical analysis of VICTORION-2P, a randomized phase 3 trial evaluating inclisiran for prevention of cardiovascular events in participants with established atherosclerotic cardiovascular disease.
- VIEW 2Complete statistical analysis of VIEW 2, the randomized phase 3 trial comparing aflibercept with ranibizumab in wet age-related macular degeneration, including non-inferiority methodology, ANCOVA, risk differences, and reported week 52 results.
- VIEW1A detailed statistical analysis of VIEW1, the randomized phase 3 trial evaluating aflibercept injection versus ranibizumab in patients with macular degeneration, including its non-inferiority design, primary visual-acuity endpoint, ANCOVA analyses, and reported…
- VIKING-3Independent statistical analysis of the VIKING-3 phase 3 trial of dolutegravir in HIV-infected subjects with treatment failure on an integrase inhibitor-containing regimen, including endpoint definitions, reported estimates, confidence intervals, statistical methods, and…
- VIOLETIndependent statistical analysis of A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- VISSITIndependent statistical analysis and educational interpretation of VISSIT (NCT00816166), a randomized phase 2/3 trial of the Pharos Vitesse Neurovascular Stent System plus medical therapy versus medical therapy for ischemic stroke and transient…
- VIVID-1Independent statistical analysis of A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03926130).
- VOYAGERIndependent statistical analysis of A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- VOYAGER PADA detailed independent statistical analysis of VOYAGER PAD, the randomized phase 3 trial of rivaroxaban plus aspirin versus placebo plus aspirin in symptomatic peripheral artery disease undergoing lower-extremity peripheral revascularization.
- WAKE-UPIndependent statistical analysis of the WAKE-UP phase 3 trial evaluating MRI-based thrombolysis with alteplase in wake-up stroke, including design, endpoints, planned statistical methods, and interpretation.
- WARCEFComplete statistical analysis of the WARCEF trial, comparing warfarin with aspirin in patients with reduced cardiac ejection fraction, including trial design, time-to-event endpoints, Cox and Poisson regression, reported results, safety, and statistical…
- WASIDIndependent statistical analysis of WASID, a randomized, double-blind phase 3 trial comparing aspirin and warfarin for stroke prevention. The page explains the trial design, available registry information, planned statistical interpretation, and important…
- WISARDIndependent statistical analysis of Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With…
- YES-PIndependent statistical analysis of Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…